FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]

연구 용도로만 사용. 전체 공지 →

연구/Highlighting the discovery of MOTS-c's anti-tumor effects in ovarian cancer and its potential as a novel therapeutic target.
연구 도서관으로 돌아가기
MOTS-c

Highlighting the discovery of MOTS-c's anti-tumor effects in ovarian cancer and its potential as a novel therapeutic target.

May 16, 2026
Share

원본 논문

Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination.

Yin Yadong et al.Advanced science (Weinheim, Baden-Wurttemberg, Germany)2024
Emergent 연구

이 주제에 대한 잠재적인 결과가 있지만 추가 검증이 필요합니다. 이러한 발견은 유망하지만 확실하지 않습니다.

이 분석에 대해 알아보기

이 기사는 위의 원본 논문에서 발견한 결과를 피테이드 연구 커뮤니티에게 이해하기 쉬운 언어로 분해합니다. 우리의 목표는 가장 중요한 사항을 강조하는 것입니다 — 실용적 의미, 증거의 강도, 그리고 현재 진행 중인 연구에 대한 의미.

MOTS-c: A Promising New Player in Ovarian Cancer Treatment

Published: May 16, 2026 | Source: Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2024) | Category: MOTS-c

Overview

A recent study published in Advanced Science has uncovered a potential new therapeutic target for ovarian cancer (OC): the mitochondrial-derived peptide MOTS-c. This research highlights how MOTS-c can inhibit OC cell proliferation and migration by targeting specific cellular pathways, suggesting its role as a promising candidate for future clinical interventions.

Study Background

Mitochondria are not only energy-producing organelles but also play critical roles in signaling and maintaining cellular homeostasis through the release of various peptides. One such peptide is MOTS-c (mitochondrial open reading frame of the 12S rRNA C), which has been previously implicated in metabolic regulation and aging processes. However, its role in cancer progression was largely unknown until this recent study.

What the Research Found

The research team discovered that MOTS-c levels are significantly reduced in both serum and tumor tissues from OC patients compared to healthy controls. This reduction correlates with poorer patient prognosis. When exogenous MOTS-c is introduced into OC cells, it inhibits their proliferation, migration, and invasion capabilities while inducing cell cycle arrest and apoptosis.

Mechanistically, the study identified that MOTS-c interacts directly with LARS1 (Leucyl-tRNA synthetase 1), a protein known to play an oncogenic role in OC. By promoting LARS1 ubiquitination and subsequent proteasomal degradation, MOTS-c effectively suppresses its oncogenic function. Additionally, the study revealed that USP7 (Ubiquitin Specific Peptidase 7) acts as a deubiquitinase for LARS1, thereby stabilizing it. However, MOTS-c competes with USP7 to bind LARS1, thus attenuating this stabilization process.

What This Means for Peptide Users

While the findings are promising, it's important to note that this study primarily focuses on in vitro and preclinical models of OC. For peptide users interested in therapeutic applications, these results suggest a potential future role for MOTS-c or similar peptides in targeted cancer therapies. However, further research is necessary before clinical application can be considered.

Limitations and Caveats

The study lacks detailed information regarding the sample size used for human subjects, which limits its statistical power and generalizability to broader populations. Additionally, while preclinical models demonstrated a marked anti-tumor effect of MOTS-c without systemic toxicity, these findings need validation in larger animal studies and eventually in human clinical trials.

How This Compares to Previous Research

Previous research has highlighted the role of mitochondrial peptides like MOTS-c in metabolic regulation but did not specifically address their involvement in cancer progression. The current study builds upon this foundation by elucidating a novel mechanism through which MOTS-c can suppress OC growth, thereby bridging the gap between mitochondrial signaling and oncogenesis.

Our Analysis

The research provides compelling evidence for the potential of MOTS-c as a therapeutic agent against ovarian cancer. However, given its preliminary nature and focus on preclinical models, it is crucial to approach these findings with caution until further validation in human subjects is achieved. The study's detailed mechanistic insights offer valuable groundwork for future investigations into mitochondrial peptides' roles in cancer biology.

Key Takeaways

  • MOTS-c levels are reduced in ovarian cancer patients, correlating with poorer prognosis.
  • Exogenous MOTS-c inhibits OC cell proliferation and migration by targeting LARS1 via USP7 interaction.
  • The study highlights the potential of MOTS-c as a therapeutic target but requires further validation in clinical settings.

Original Source

Citation: Yin Yadong, Li Yujie, Ma Boyi et al. (2024). Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination.. Advanced science (Weinheim, Baden-Wurttemberg, Germany). DOI: 10.1002/advs.202405620

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

편집자의 주석

이 분석은 Peptide Contacts 연구 팀에 의해 작성되었습니다. 항상 원문을 참조하고 자격 있는 의료 전문가와 상담하기 위해 원본 논문 전체 방법론 및 데이터는 여기에서 확인하실 수 있습니다. 원래 출판물은 {source}에서 확인하실 수 있습니다. PubMed.

관련 연구

Comments

Sign in to join the discussion

이 분석은 교차 검토된 연구를 기반으로 교육 목적용으로 생성되었습니다. 이 내용은 의학적 조언으로 간주되지 않습니다. 피테이드 기반 치료법을 사용하기 전에 항상 자격 있는 의료 전문가와 상담하십시오.